The intellectual disability of trisomy 21: differences in gene expression in a case series of patients with lower and higher IQ

• DOI: 10.1038/ejhg.2013.24
• Publication Date: 2013-02-20T11:21:00Z
• Authors: André Mégarbané; Florian Noguier; Samantha Stora; Laurent Manchon; Clotilde Mircher; Roman Bruno; Nathalie Dorison; Fabien Pierrat; Marie-Odile Rethoré; Bernadette Trentin; Aimé Ravel; Marine Morent; Gerard Lefranc; David Piquemal
• Keywords: Adult; Intelligence Tests; Male; 0303 health sciences; Adolescent; [SDV]Life Sciences [q-bio]; Gene Expression Profiling; [SDV.BC]Life Sciences [q-bio]/Cellular Biology; HLA-DQ alpha-Chains; Young Adult; 03 medical and health sciences; Gene Expression Regulation; Case-Control Studies; Intellectual Disability; Humans; Female; RNA, Messenger; Down Syndrome; HLA-DRB1 Chains

Trisomy 21 (T21), or Down syndrome (DS), is the most frequent and recognizable cause of intellectual disabilities. The level of disability, as evaluated by the intelligence quotient (IQ) test, varies considerably between patients independent of other factors. To determine the genetic or molecular basis of this difference, a high throughput transcriptomic analysis was performed on twenty T21 patients with high and low IQ, and 10 healthy controls using Digital Gene Expression. More than 90 millions of tags were sequenced in the three libraries. A total of 80 genes of potential interest were selected for the qPCR experiment validation, and three housekeeping genes were used for normalizing purposes. HLA DQA1 and HLA DRB1 were significantly downregulated among the patients with a low IQ, the values found in the healthy controls being intermediate between those noted in the IQ+ and IQ- T21 patients. Interestingly, the intergenic region between these genes contains a binding sequence for the CCCTC-binding factor, or CTCF, and cohesin (a multisubunit complex), both of which are essential for expression of HLA DQA1 and HLA DRB1 and numerous other genes. Our results might lead to the discovery of genes, or genetic markers, that are directly involved in several phenotypes of DS and, eventually, to the identification of potential targets for therapeutic interventions.